Summary
Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor (AR)-targeted agents is often lethal. Unfortunately, biomarkers for this deadly disease remain under investigation, and underpinning mechanisms are ill-understood. Here, we applied deep sequencing to ∼100 mCRPC patients prior to the initiation of first-line AR-targeted therapy, which detected AR/enhancer alterations in over a third of patients, which correlated with lethality. To delve into the mechanism underlying why these patients with cell-free AR/enhancer alterations developed more lethal prostate cancer, we next performed genome-wide cell-free DNA epigenomics. Strikingly, we found that binding sites for transcription factors associated with developmental stemness were nucleosomally more accessible. These results were corroborated using cell-free DNA methylation data, as well as tumor RNA sequencing from a held-out cohort of mCRPC patients. Thus, we validated the importance of AR/enhancer alterations as a prognostic biomarker in lethal mCRPC, and showed that the underlying mechanism for lethality involves reprogramming developmental states toward increased stemness.
Competing Interest Statement
P.S.C., I.A., and A.A.C. have patent filings related to cancer biomarkers. F.Q. has stock options in Centene, Gilead, and Horizon Therapeutics. O.S. served as a consultant to JNJ and Pfizer and grant support to institution for JNJ. R.P. has licensed technology to Tempus Labs and have served as advisory to AstraZeneca, Bayer, BMS, Blue Earth Diagnostics, Dendreon, Genentech/Roche, Genomic Health, EMD Serono, Janssen, Merck, Pfizer, Sanofi-Aventis, Tempus, Tolmar Therapeutics and research funding from BMS, Exelixis, Janssen, Genentech/Roche, Pharmacyclics. C.A.M. has also licensed technology and serving as consultant to Tempus. A.A.C. has patent filings related to cancer biomarkers, and has licensed technology to Droplet Biosciences, Tempus Labs and to Biocognitive Labs. A.A.C. has served as a consultant/advisor to Roche, Tempus, Geneoscopy, NuProbe, Illumina, Daiichi Sankyo, AstraZeneca, AlphaSights, DeciBio, Guidepoint, Invitae and Myriad Genetics. A.A.C. has received honoraria from Roche, Foundation Medicine, and Dava Oncology. A.A.C. has stock options in Geneoscopy, research support from Roche, Illumina and Tempus Labs, and ownership interests in Droplet Biosciences and LiquidCell Dx.
Funding Statement
We are grateful to the patients, and their families, involved in this study. Images from Biorender.com were used to create Figure 1. This work was supported by NIH under the award F31 CA265010-01 (J.W.). This work was also supported by the National Cancer Institute (NCI) under award number K08CA238711 (A.A.C.), and the National Center for Advancing Translational Sciences (NCATS) under award number UL1TR002345 (Principal Investigator, Bradley Evanoff; A.A.C.). This work was additionally supported by LEAP competition through the Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship, the Institute for Clinical and Translational Sciences, and the Siteman Cancer Center of Washington University in St. Louis under award number (Award #: 1077, A.A.C.), the Alvin J. Siteman Cancer Research Fund (A.A.C.), the Cancer Research Foundation Young Investigator Award (A.A.C.), and the V Foundation V Scholar Award (A.A.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were collected with informed consent and institutional review board approval (IRB) (Washington University IRB # 201411135 and Tulane IRB # 992885) in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors